Short Interest in PicoCELA Inc. (NASDAQ:PCLA) Expands By 113.0%

PicoCELA Inc. (NASDAQ:PCLA) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 429,834 shares, an increase of 113.0% from the July 15th total of 201,780 shares. Based on an average trading volume of 146,360 shares, the short-interest ratio is presently 2.9 days. Currently, 1,074.6% of the shares of the company are short sold.

Institutional Investors Weigh In On PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. XTX Topco Ltd acquired a new stake in shares of PicoCELA Inc. (NASDAQ:PCLA) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned approximately 0.16% of PicoCELA at the end of the most recent reporting period.

PicoCELA Stock Performance

Shares of NASDAQ:PCLA traded up $0.42 during trading on Friday, hitting $6.76. 265,414 shares of the company’s stock were exchanged, compared to its average volume of 357,809. The business’s 50-day simple moving average is $5.41 and its 200 day simple moving average is $4.32. PicoCELA has a 52-week low of $1.35 and a 52-week high of $19.61.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on PCLA shares. Weiss Ratings lowered shares of PicoCELA from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 3rd. Wall Street Zen upgraded shares of PicoCELA to a “hold” rating in a research report on Saturday, July 25th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.